Vincerx Pharma Announces First Patient Dosed in Phase 1b Study of VIP152 in MYC-Driven Relapsed or Refractory Aggressive Lymphomas and Advanced Solid Tumors
First patient dosed by Vincerx marks significant milestone in Company’s developmentPALO ALTO, Calif., June 03, 2021 (GLOBE NEWSWIRE) — Vincerx…